Is there a role for population-wide testing?

Large-scale screening rapid antigen tests campaigns among the general population may seem to be a promising technique for guiding containment efforts, however the difficulties associated with such a strategy should not be underestimated, and the success of such campaigns remains in doubt.

First and foremost, testing millions of individuals per week, along with all of the necessary pre-and post-analytical work, is a time-consuming and labor-intensive process. For the second time, rapid antigen tests are the only viable choice at this time in terms of capacity and cost for testing on a large scale, such as millions of individuals. lean more about rapid antigen test commonly called RAT at

However, given their existing lower performance, as has been stated above, there are difficulties. However, even if the performance of rapid antigen tests continues to improve over time, the issue of low prevalence in the general population and, therefore, the large number of false positives will continue to be a concern.

In other words, a significant number (perhaps as much as more than 50%) of all “positive” rapid antigen tests will be false positives in reality. If persons with a positive test result are expected to isolate themselves, as would be required for the technique to be successful, this has the potential to undermine their acceptance of the rapid antigen tests.

This is tough to manage at a large scale. Because of this, many individuals would have limitations in their everyday life, including their capacity to work, even if they did not have the virus in their system. If such a scenario is possible, policymakers must assess if there is enough public support for it to be implemented successfully. Click here to read some good tips that you can try at home while performing rapid antigen tests.

Mass screening is only successful if individuals are willing to be tested and if those who are recognized as positive isolate swiftly. People may be reluctant to isolate if they have doubts about the authenticity of the test findings, which is particularly true if they believe the results are bogus.

A number of nations are now experimenting with population-wide screening, but the results have been inconsistent so far, and the projects are proving difficult and expensive to implement. From a technical aspect, next-generation sequencing (NGS) has the potential to be an acceptable option in the future, depending on the circumstances.

However, this rapid antigen tests technology is still in the early stages of development. NGS is a highly sensitive and specific test modality that has the capability of delivering extraordinarily high throughput rates at extremely low costs. Some firms and labs are expanding COVID 19 testing capacity via the use of next-generation sequencing (NGS), which can test up to 10,000 samples at a time with a turnaround time of 24 to 48 hours for findings.

What should I do if the COVID-19 rapid antigen tests results are negative?

In humans, the COVID-19 rapid antigen tests are a rapid membrane-based lateral flow immunoassay that can be used to identify SARS-CoV-2 antigens in nasopharyngeal swab specimens in less than an hour. It is possible to identify the presence of SARS-CoV-2 viral antigens in human bodies with the use of a COVID-19 rapid antigen tests, which may then be used to initiate preventive isolation measures in order to minimize the spread of the virus. A person who is at or near the peak of infection may be identified using one of these rapid antigen tests. So the issue becomes, how should I interpret the results of the antigen quick test?

Structure of the COVID-19 rapid antigen tests Cassette

The antigen test cassette for COVID-19 is coated with two lines of antigen (the control line and the test line). A colored line will appear on the test strip if the specimen has SARS-CoV-2 antigens, suggesting that the specimen contains SARS-CoV-2 antibodies coated on the (T) Test line area and that the specimen contains SARS-CoV-2 antigens. 

A negative result is shown by the absence of a colored line in the (T) Test line area, which indicates that the antigens were not present in the material. It is always possible to see a colored line in the (C) Control line section, which indicates that the test method was followed correctly and that the test components worked as planned.

Results of the Valid rapid antigen tests

Two colorful lines emerge as a result of a successful test.

It is essential that a colored line appears in the Control (C) section at all times, and that another line appears in the Test (T). Antigens for SARS-CoV-2 have been detected in the sample, resulting in a positive result.

When the instructions are carefully followed, a positive antigen test result is considered accurate; however, there is an increased chance of false-negative results — meaning it is possible to be infected with the virus while having a negative result — when the instructions are not carefully followed.

A colored line emerges in the Control (C) zone as a result of a negative result.

In the Test (T) area, there is no line to be seen.

In order for the test to be legitimate, a colored line should always appear in the Control (C) zone, just as it does in the case of a positive result. A negative result indicates that the detection threshold for SARS-CoV-2 antigens in the sample has not been met in this particular case. Even if the quantity of antigens in the sample is too low to be identified by the rapid antigen tests, there is still a risk of infection developing in the sample.

Don’t use these results in the absence of the control line.

Generally speaking, insufficient diluent volume or inappropriate procedural procedures are the most frequent causes of the disappearance of the control line in the sample. Review the protocol and do the test with a different instrument if necessary.

Rapid antigen tests are generally affordable, and the majority of them may be performed right at the patient’s bedside. The majority of the rapid antigen tests that are now permitted produce findings in around 15 minutes. When it comes to identifying the presence of viral nucleic acid, antigen testing for SARS-CoV-2 are often less sensitive than real-time reverse transcription polymerase chain reaction (RT-PCR) and other nucleic acid amplification rapid antigen tests (NAATs). RT-PCR, on the other hand, may detect amounts of viral nucleic acid that cannot be grown, indicating that the presence of viral nucleic acid does not necessarily signal the existence of contagiousness.

Please make a decision on the results of gotten from the rapid antigen results within 15-30 minutes of receiving them. If you check again in a few hours, the result will no longer be valid.

Rapid antigen tests solution you can try at home

Testing is critical in the battle against the enormous COVID-19 outbreak that has swept the world. Immunodiagnostic Systems (IDS) is pleased to provide you with a comprehensive range of COVID-19 rapid antigen tests that are dependable and of high quality.

  • Distribute 
  • Print 
  • Request further information

Which test should I use and when should I use it?

It is important to have reliable diagnostic rapid antigen tests that can distinguish between individuals who are actively infected by the virus and those who have mounted an immune response against the virus. However, it is critical to understand which rapid antigen tests are most appropriate to apply based on the purpose for which they are meant.

There are two main forms of COVID-19 testing available: a test for current infection (diagnostic test) and a test for recent or prior infection (antibody test), which is also known as a recent or previous infection test.

Diagnostic Test for the Present Infection

It is necessary to do a diagnostic test in order to determine the existence of the virus; consequently, it is symptomatic of an active infection. This sort of test is often performed using a nose or throat swab to evaluate the patient’s health. The molecular and antigen methods are among the technologies used in diagnostic rapid antigen tests.

Genetic material from the virus is detected by molecular testing, often known as RT-PCR (Reverse transcription-polymerase chain reaction) assays. The majority of molecular testing is carried out in a laboratory environment.

Antigen tests look for particular proteins produced by the virus and identify them. When doing an antigen test, you may choose between using an automated laboratory instrument or performing a quick test that does not need any laboratory equipment, making the latter option ideal for usage in any situation.

Antibody Test for Infections that have occurred recently or previously

An antibody test is used to determine whether or not a person has been recently or previously infected with a virus. This test is often conducted by the use of a blood sample.

In order to determine the efficiency of vaccinations and medicines, it is necessary to determine if a person has recently or previously been infected with SARS-CoV-2, as well as the amount of antibodies in their bloodstream.

The Use of IDS Systems for Antigen Testing II

A current infection is detected by detecting SARS-CoV-2 antigens, which are viral surface proteins that elicit an immunological response from the patient.

Antigen tests involve the evaluation of a nasal or throat swab. These rapid antigen tests can be performed in a clinical laboratory on specific equipment that typically provides results in hours, or they can be performed using a simple, rapid test format that typically requires no laboratory equipment and provides results in 15 minutes or less (assay dependent).

Rapid SARS-CoV-2 antigen testing is a simple yet effective approach for identifying persons who are currently infected with the virus and enabling the deployment of contact tracing procedures to assist prevent the spread of the illness. Click here to learn more about contact tracing procedures.

These rapid antigen tests are easy to use, needing no specialized training or equipment to conduct, allowing them to be used in any situation, including close proximity to patients, the workplace, schools, and other institutions.

With the use of a direct nasopharyngeal (NP) swab, IDS provides the following rapid antigen tests to identify the presence of SARS-CoV-2 Nucleocapsid protein antigen in the blood. These easy-to-use antigen tests provide results in as little as 15 minutes and do not need any special laboratory equipment.

  • Cassette (Swab) for Coronavirus Ag Rapid Testingii
  • Kit for the Rapid Detection of SARS-CoV-2 Antigenii

Integrated Diagnostics Solutions for Antibody Testing

Specific IgM antibody levels are frequently elevated three to five days following the beginning of symptoms in response to viral infections, with the peak occurring three to five days later. The existence of these antibodies is usually detectable for thirty to sixty days after the injection. IgG levels normally become increased after ten to fourteen days and might stay detectable for many years after that time period has passed.

Because each individual’s seroconversion process is unique, it is critical to distinguish between IgG and IgM antibodies separately. The IgM and IgG rapid antigen tests may be used in conjunction to detect antibodies in both symptomatic and asymptomatic people.

It is possible to identify the presence of antibodies (IgG and IgM) against SARS-CoV-2 utilizing serum, plasma, or whole blood using the fast antigen assays offered by International Diagnostic Systems (IDS). This easy-to-use antibody test provides results in as little as 15 minutes and does not need the use of expensive laboratory equipment.

TGS Velox Ab COVID-19 IgM/IgG POCTii is a monoclonal antibody against COVID-19.

The following antibody rapid antigen tests are available from IDS for use in a laboratory setting:

IDS SARS-CoV-2 IgG is a qualitative detection of IgG antibodies to SARS-CoV-2 in human serum and plasma using the IDS-iSYS Multi-Disciplinary Automated System. It is a completely automated qualitative detection of IgG antibodies to SARS-CoV-2 in human serum and plasma. Only for usage in situations requiring an Emergency Use Authorization (EUA).

A completely automated QUANTITATIVE chemiluminescent test for the detection of persons who have developed an adaptive immune response to SARS-CoV-2, suggesting recent or past infection, is available from TGS COVID-19 IgGii.

In the event that effective SARS-CoV-2 vaccines become available, the presence of antibodies will be an essential sign of a person’s immunological response to the virus. As a result, the levels of anti-SARS-CoV-2 antibody response may be useful in determining the efficiency of vaccinations and therapy.

It is possible to identify antibodies that arise early in the course of an infection using the TGS COVID-19 IgMii test, which is a completely automated chemiluminescent assay.

The automated IgG and IgM rapid antigen tests on the IDS system may be performed in conjunction with one another to offer the most accurate picture of the patient’s immune response. When the IgM and IgG values are combined, there is 95.8 percent agreement between positive samples and RT-PCR after 7 days of diagnosis, and 98.6 percent agreement between supposed negative samples after 7 days of diagnosis.

Open automated ELISA systems are compatible with the ErbaLisa® COVID-19 IgGii and ErbaLisa® COVID-19 IgM ELISAii testing solutions for the COVID-19 antigen.